Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents

Toyoaki Hida, Ken ichi Kozaki, Hidemi Ito, Osamu Miyaishi, Yoshio Tatematsu, Takeshi Suzuki, Keitaro Matsuo, Takahiko Sugiura, Makoto Ogawa, Toshitada Takahashi, Takashi Takahashi

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

This study reports that a selective COX-2 inhibitor JTE-522 inhibits both in vitro and in vivo growth of human lung cancer cells as a single agent. Furthermore, the adjunct use of JTE-522 is shown to significantly enhance treatment efficacy of conventional anticancer drugs not only in vitro but also in vivo without causing any noticeable side effects. Indeed, IC50s of various anticancer agents in vitro were reduced by up to 70%, whereas the combination therapy of JTE-522 with docetaxel and vinorelbine inhibited tumor growth in vivo by 65 and 55%, respectively. Taken together, these findings suggest that the use of a selective COX-2 inhibitor in the treatment of lung cancer may be promising, especially because of its enhancement of the treatment efficacy of conventional anticancer agents without compromising quality of life.

Original languageEnglish
Pages (from-to)2443-2447
Number of pages5
JournalClinical Cancer Research
Volume8
Issue number7
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Cyclooxygenase 2 Inhibitors
Antineoplastic Agents
Lung Neoplasms
docetaxel
Growth
Quality of Life
Pharmaceutical Preparations
4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide
In Vitro Techniques
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. / Hida, Toyoaki; Kozaki, Ken ichi; Ito, Hidemi; Miyaishi, Osamu; Tatematsu, Yoshio; Suzuki, Takeshi; Matsuo, Keitaro; Sugiura, Takahiko; Ogawa, Makoto; Takahashi, Toshitada; Takahashi, Takashi.

In: Clinical Cancer Research, Vol. 8, No. 7, 2002, p. 2443-2447.

Research output: Contribution to journalArticle

Hida, T, Kozaki, KI, Ito, H, Miyaishi, O, Tatematsu, Y, Suzuki, T, Matsuo, K, Sugiura, T, Ogawa, M, Takahashi, T & Takahashi, T 2002, 'Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents', Clinical Cancer Research, vol. 8, no. 7, pp. 2443-2447.
Hida, Toyoaki ; Kozaki, Ken ichi ; Ito, Hidemi ; Miyaishi, Osamu ; Tatematsu, Yoshio ; Suzuki, Takeshi ; Matsuo, Keitaro ; Sugiura, Takahiko ; Ogawa, Makoto ; Takahashi, Toshitada ; Takahashi, Takashi. / Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. In: Clinical Cancer Research. 2002 ; Vol. 8, No. 7. pp. 2443-2447.
@article{1a9ef327a4db484283c2fc8c05f9a3cd,
title = "Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents",
abstract = "This study reports that a selective COX-2 inhibitor JTE-522 inhibits both in vitro and in vivo growth of human lung cancer cells as a single agent. Furthermore, the adjunct use of JTE-522 is shown to significantly enhance treatment efficacy of conventional anticancer drugs not only in vitro but also in vivo without causing any noticeable side effects. Indeed, IC50s of various anticancer agents in vitro were reduced by up to 70{\%}, whereas the combination therapy of JTE-522 with docetaxel and vinorelbine inhibited tumor growth in vivo by 65 and 55{\%}, respectively. Taken together, these findings suggest that the use of a selective COX-2 inhibitor in the treatment of lung cancer may be promising, especially because of its enhancement of the treatment efficacy of conventional anticancer agents without compromising quality of life.",
author = "Toyoaki Hida and Kozaki, {Ken ichi} and Hidemi Ito and Osamu Miyaishi and Yoshio Tatematsu and Takeshi Suzuki and Keitaro Matsuo and Takahiko Sugiura and Makoto Ogawa and Toshitada Takahashi and Takashi Takahashi",
year = "2002",
language = "English",
volume = "8",
pages = "2443--2447",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents

AU - Hida, Toyoaki

AU - Kozaki, Ken ichi

AU - Ito, Hidemi

AU - Miyaishi, Osamu

AU - Tatematsu, Yoshio

AU - Suzuki, Takeshi

AU - Matsuo, Keitaro

AU - Sugiura, Takahiko

AU - Ogawa, Makoto

AU - Takahashi, Toshitada

AU - Takahashi, Takashi

PY - 2002

Y1 - 2002

N2 - This study reports that a selective COX-2 inhibitor JTE-522 inhibits both in vitro and in vivo growth of human lung cancer cells as a single agent. Furthermore, the adjunct use of JTE-522 is shown to significantly enhance treatment efficacy of conventional anticancer drugs not only in vitro but also in vivo without causing any noticeable side effects. Indeed, IC50s of various anticancer agents in vitro were reduced by up to 70%, whereas the combination therapy of JTE-522 with docetaxel and vinorelbine inhibited tumor growth in vivo by 65 and 55%, respectively. Taken together, these findings suggest that the use of a selective COX-2 inhibitor in the treatment of lung cancer may be promising, especially because of its enhancement of the treatment efficacy of conventional anticancer agents without compromising quality of life.

AB - This study reports that a selective COX-2 inhibitor JTE-522 inhibits both in vitro and in vivo growth of human lung cancer cells as a single agent. Furthermore, the adjunct use of JTE-522 is shown to significantly enhance treatment efficacy of conventional anticancer drugs not only in vitro but also in vivo without causing any noticeable side effects. Indeed, IC50s of various anticancer agents in vitro were reduced by up to 70%, whereas the combination therapy of JTE-522 with docetaxel and vinorelbine inhibited tumor growth in vivo by 65 and 55%, respectively. Taken together, these findings suggest that the use of a selective COX-2 inhibitor in the treatment of lung cancer may be promising, especially because of its enhancement of the treatment efficacy of conventional anticancer agents without compromising quality of life.

UR - http://www.scopus.com/inward/record.url?scp=0035992439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035992439&partnerID=8YFLogxK

M3 - Article

C2 - 12114451

AN - SCOPUS:0035992439

VL - 8

SP - 2443

EP - 2447

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -